logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Verrica Pharmaceuticals Announced the FDA Granted YCANTHTM New Chemical Entity Status and Orange Book Listing

We are currently working to bring into the upcoming ProhostBiotech Letter some small clinical and commercial innovating firms that are challenging the Top-Tier firms that are currently generating billions of dollars in selling revenues.  These firms are developers of products...

Read More

March 28, 2024

0

Syndax Pharmaceuticals: Positive Pediatric Data from Pivotal Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals in the NEWS Yesterday, Syndax Pharmaceuticals (NASDAQ: SNDX ) announced the presentation of positive data from the pivotal AUGMENT-101 trial in pediatric patients with relapsed/refractory ( R/R ) KMT2A-rearranged ( KMT2Ar ) acute myeloid leukemia ( AML )...

Read More

April 9, 2024

0

Answers About Vertex Pharmaceuticals Acquisition of Alpine Immune. See Also: Important News from Coya Therapeutics on ALS

Vertex Pharmaceuticals Acquisition of Alpine Immune Sciences We start this posting by answering a question by savvy investors regarding Vertex Pharmaceuticals' ( VRTX ) decision to acquire Alpine Immune Sciences ( ALPN ) . The reason for the question is...

Read More

April 11, 2024

0

Voyager Therapeutics: Demonstrating Productivity in Collaboration with Neurocrine to Advance Gene Therapies for Neurological Diseases

Voyager Therapeutics  Voyager Therapeutics ( VYGR ) is a biotech company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. The firm’s pipeline includes programs for Alzheimer’s disease, amyotrophic...

Read More

April 17, 2024

0

Vertex and TreeFrog Therapeutics Announced Licensing Agreement and Collaboration to Optimize Production of Vertex Cell Therapies for Type 1 Diabetes

Vertex Pharmaceuticals and TreeFrog Therapeutics in the NEWS Vertex Pharmaceuticals  ( VRTX ) and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog’s proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex’s cell therapies for Type...

Read More

April 25, 2024

0

Vertex Pharmaceuticals Reports First Quarter 2024 Financial Results

Vertex Pharmaceuticals Vertex Pharmaceuticals ( VRTX ) reported consolidated financial 2024 results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance. Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex Pharmaceuticals said, “Vertex...

Read More

May 7, 2024

0

Verrica Pharmaceuticals: Collaboration and License Agreements for the Treatment of Skin Diseases Other Than Molluscum Contagiosum

Verrica Pharmaceuticals Verrica Pharmaceuticals’ ( VRCA ) product YCANTH ( cantharidin ) is the only commercially available treatment approved by the FDA for the treatment of adults and pediatric patients two years of age and older with Molluscum Contagiosum. Molluscum...

Read More

May 16, 2024

0

Pivotal Data About Efficacy and Tolerability of Arcturus Therapeutics’ COVID-19 Vaccine Published in Nature Communications  

Arcturus Therapeutics COVID-19 Vaccine Published CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics ( ARCT ) announced that Journal Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT-154, a novel self-amplifying (sa-mRNA)...

Read More

May 22, 2024

0

Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting 

Moderna to Host Investor Event Via Webcast Moderna, Inc. ( MRNA ) announced that three abstracts on mRNA-4157 ( V940 ), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2024 American Society of Clinical Oncology...

Read More

May 23, 2024

0

Ionis Pharmaceuticals Presented Positive Results from Two Late Studies of investigational Product Donidalorsen

Ionis Parmaceuticals Treating Hereditary Angioedema On May 31, 2024, Ionis Pharmaceuticals ( IONS ) announced positive results from two Phase 3 OASIS-HAE and OASIS plus studies of the firm’s Donidalorsen in patients with hereditary angioedema ( HAE ). Donidalorsen demonstrating...

Read More

June 3, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 73
  • 74
  • 75
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy